Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026)

Avalo Therapeutics has reported Net Cash Flow for 13 years, with the latest figure at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 197.32% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at -$100.0 million (down 769.78% YoY), and the FY2025 full-year result was -$118.6 million, down 193.3% from the prior year.
• Net Cash Flow for Q1 2026 stood at $9.2 million, up from -$11.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $102.8 million in Q1 2024, with the low at -$82.7 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$1.7 million across 5 years, with a median of -$9.5 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 1444.51% — and 2024, when it surged 2784.25%.
• Avalo Therapeutics' Net Cash Flow stood at -$3.9 million in 2022, then climbed by 28.33% to -$2.8 million in 2023, then surged by 2004.7% to $52.7 million in 2024, then plunged by 121.27% to -$11.2 million in 2025, then soared by 182.18% to $9.2 million in 2026.
• The last three Net Cash Flow figures came in at $9.2 million (Q1 2026), -$11.2 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.